OCUL logo

OCUL
Ocular Therapeutix Inc

10,604
Mkt Cap
$2.58B
Volume
2.66M
52W High
$13.85
52W Low
$5.79
PE Ratio
-8.42
OCUL Fundamentals
Price
$11.72
Prev Close
$12.10
Open
$12.23
50D MA
$11.74
Beta
1.57
Avg. Volume
3.29M
EPS (Annual)
-$1.22
P/B
8.20
Rev/Employee
$232,565.69
Loading...
Loading...
News
all
press releases
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet
The consensus price target hints at an 82.5% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·7h ago
News Placeholder
More News
News Placeholder
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have received a consensus rating of "Moderate Buy" from the fourteen analysts that are covering the stock, MarketBeat.com reports...
MarketBeat·14h ago
News Placeholder
Ocular Therapeutix (NASDAQ:OCUL) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen lowered Ocular Therapeutix from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·5d ago
News Placeholder
Chardan Capital Issues Optimistic Forecast for OCUL Earnings
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Stock analysts at Chardan Capital lifted their FY2025 earnings estimates for Ocular Therapeutix in a note issued to investors on Wednesday...
MarketBeat·11d ago
News Placeholder
Y Intercept Hong Kong Ltd Buys New Holdings in Ocular Therapeutix, Inc. $OCUL
Y Intercept Hong Kong Ltd purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 2nd quarter, according to the company in its most recent filing with the...
MarketBeat·11d ago
News Placeholder
HC Wainwright Cuts Earnings Estimates for Ocular Therapeutix
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Equities research analysts at HC Wainwright reduced their Q4 2025 earnings per share (EPS) estimates for Ocular Therapeutix in a report issued...
MarketBeat·12d ago
News Placeholder
Ocular Therapeutix (NASDAQ:OCUL) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating...
MarketBeat·14d ago
News Placeholder
Ocular Therapeutix (NASDAQ:OCUL) Receives Buy Rating from Chardan Capital
Chardan Capital reiterated a "buy" rating and set a $21.00 target price on shares of Ocular Therapeutix in a research report on Wednesday...
MarketBeat·14d ago
News Placeholder
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +5.13% and +8.89%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 82.93%: Here's is How to Trade
The consensus price target hints at an 82.9% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·21d ago

Latest OCUL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.